Press Releases
Valiltramiprosate is an investigational agent and not approved for use anywhere in the world. Statements in news stories may be aspirational.
Alzheon to Present New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in APOE4/4 Alzheimer’s Patients at AAIC 2026 Conference in London
Phase 3 and Phase 2 Studies in APOE4/4 Alzheimer’s Patients Show Favorable Safety, Low Risk for Brain Bleed and Edema (ARIA), and Neurovascular Protection
Alzheon to Present Evidence of Neurovascular Protection from Trials with Oral Valiltramiprosate in APOE4/4 Alzheimer’s Patients Leading to Reduced Brain Edema and Microhemorrhage Risk at 2026 American Academy of Neurology Meeting in Chicago, Illinois
Valiltramiprosate Shows Favorable Safety Outcomes with Low ARIA Risk and Evidence of Neurovascular Protection in APOE4/4 Alzheimer’s Patients
Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved Safety and Efficacy, and APOE4 Corrector Mechanism
ALZ-507 Designed as Well-Differentiated Oral Candidate Targeting Soluble Amyloid Oligomer Pathology, with Additional Mechanism of Action as APOE4 Corrector
Alzheon to Present Clinical, Imaging, and Fluid Biomarker Results from Trials with Oral Valiltramiprosate/ALZ-801 at 2026 AD/PD Conference in Copenhagen, Denmark
Valiltramiprosate Shows Promise as an Oral Potentially Disease-Modifying Agent that can Slow Alzheimer’s Disease Based on Clinical Results, MRI Data, and Fluid Biomarkers in APOE4/4 MCI [...]
Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801, Validating Its First-in-Class Mechanism of Action and Underscoring Benefits in Cognition, Function, and Brain Volume Protection in Alzheimer’s Patients
Early and Consistent Decreases in P-tau217 Plasma Levels Were Associated with Improvements in Cognition, Function, and Brain Atrophy Measures
Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer’s Disease
Comprehensive Analyses Across Interventional and Observational Trials Show that Hippocampal Atrophy Closely Tracks with Memory Loss and Disease Progression, and Is Highly Sensitive to Effects of Disease-Modifying Therapies
Alzheon to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego, December 1–4, 2025
Valiltramiprosate Demonstrates Potential as the First Oral Disease-Modifying Agent to Slow Alzheimer’s Pathology, Indicated by Both Clinical and Volumetric MRI Data
Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
Publication Describes Efficacy by Disease Severity and Highlights Prespecified Analysis of Mild Cognitive Impairment Stage Patients that Showed Cognitive and Functional Benefits, and Neuroprotective Effects on Brain Atrophy
Alzheon to Present Insights into Oral Valiltramiprosate/ALZ-801 Mode of Action and Clinical Efficacy at Dedicated Symposium at Alzheimer’s Association International Conference in Toronto on July 30th, 2025
Anti-Amyloid Oligomer Action Underpins Valiltramiprosate’s Potential Benefit in Alzheimer’s Disease at MCI Stage of Disease
Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer’s Disease Carrying Two Copies of APOE4 Gene
Valiltramiprosate Improved Cognition and Function in Prespecified Analysis in Patients at Mild Cognitive Impairment Stage
Newsletter
Sign up for updates
Get the latest Alzheon news in your inbox.
Not seeing the signup form? An ad or privacy blocker may be hiding it – email info@alzheon.com and we’ll add you to the list.
